Dr. Shah on Status of CAR T-cell Therapies in ALL
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).
The first FDA approval will likely be in pediatric ALL, Shah says. However, in the adult patients with ALL, researchers are closely behind.
However, several pharmaceutical companies have been entering the space and are actively conducting clinical trials with these agents. These therapies have the ability to produce durable remissions and improve survival, Shah says.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
